To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2018

Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects

Vol: 7| Issue: 9| Number:17| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

Clin Ther. 2007 Sep;29(9):2068-79

Contributing Authors:
TJ Nurmikko DJ Rog CA Young

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.